Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has Launched Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of NAMENDA (memantine HCL) tablets in the US market on July 12, 2015 approved by the United States Food & Drug Administration (USFDA).

The NAMENDA (memantine HCL) tablets had U.S. sales of approximately $ 1.4 billion MAT for the most recent twelve months ending in May 2015.

Company’s memantine hydrochloride tablets USP, 5 mg is available in bottle count size of 60 and the Memantine hydrochloride tablets USP, 10 mg are available in bottle count sizes of 60 and 500.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.